keyword
MENU ▼
Read by QxMD icon Read
search

statin in acute coronary syndrome

keyword
https://www.readbyqxmd.com/read/28437620/american-association-of-clinical-endocrinologists-and-american-college-of-endocrinology-guidelines-for-management-of-dyslipidemia-and-prevention-of-cardiovascular-disease
#1
Paul S Jellinger, Yehuda Handelsman, Paul D Rosenblit, Zachary T Bloomgarden, Vivian A Fonseca, Alan J Garber, George Grunberger, Chris K Guerin, David S H Bell, Jeffrey I Mechanick, Rachel Pessah-Pollack, Kathleen Wyne, Donald Smith, Eliot A Brinton, Sergio Fazio, Michael Davidson
OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Directors and American College of Endocrinology (ACE) Board of Trustees and adheres with published AACE protocols for the standardized production of clinical practice guidelines (CPGs). METHODS: Recommendations are based on diligent reviews of the clinical evidence with transparent incorporation of subjective factors, according to established AACE/ACE guidelines for guidelines protocols...
April 2017: Endocrine Practice
https://www.readbyqxmd.com/read/28430910/low-density-lipoprotein-cholesterol-targeting-with-pitavastatin-ezetimibe-for-patients-with-acute-coronary-syndrome-and-dyslipidaemia-the-hij-proper-study-a-prospective-open-label-randomized-trial
#2
Nobuhisa Hagiwara, Erisa Kawada-Watanabe, Ryo Koyanagi, Hiroyuki Arashi, Junichi Yamaguchi, Koichi Nakao, Tetsuya Tobaru, Hiroyuki Tanaka, Toshiaki Oka, Yasuhiro Endoh, Katsumi Saito, Tatsuro Uchida, Kunihiko Matsui, Hiroshi Ogawa
Aims: To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less than 100 mg/dL (2.6 mmol/L). Methods and Results: The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe reduces cardiovascular events more than standard LDL-C lowering with pitavastatin monotherapy in patients with acute coronary syndrome (ACS) and dyslipidaemia...
April 18, 2017: European Heart Journal
https://www.readbyqxmd.com/read/28428204/flow-perturbation-mediates-neutrophil-recruitment-and-potentiates-endothelial-injury-via-tlr2-in-mice-implications-for-superficial-erosion
#3
Grégory Franck, Thomas Mawson, Grasiele Sausen, Manuel Salinas, Gustavo Santos Masson, Andrew P Cole, Marina Beltrami Moreira, Yiannis Chatzizisis, Thibaut Quillard, Yevgenia Tesmenitsky, Eugenia Shvartz, Galina K Sukhova, Filip K Swirski, Matthias Nahrendorf, Elena Aikawa, Kevin Croce, Peter Libby
Rationale: Superficial erosion currently causes up to a third of acute coronary syndromes (ACS), yet we lack understanding of its mechanisms. Thrombi due to superficial intimal erosion characteristically complicate matrix-rich atheromata in regions of flow perturbation. Objective: This study tested in vivo the involvement of disturbed flow, and of neutrophils, hyaluronan, and TLR2 ligation in superficial intimal injury, a process implicated in superficial erosion. Methods and Results: In mouse carotid arteries with established intimal lesions tailored to resemble the substrate of human eroded plaques, acute flow perturbation promoted downstream endothelial cell (EC) activation, neutrophil accumulation, EC death and desquamation, and mural thrombosis...
April 20, 2017: Circulation Research
https://www.readbyqxmd.com/read/28427340/does-the-association-between-adherence-to-statin-medications-and-mortality-depend-on-measurement-approach-a-retrospective-cohort-study
#4
Mhd Wasem Alsabbagh, Dean Eurich, Lisa M Lix, Thomas W Wilson, David F Blackburn
BACKGROUND: The aim of this study was to examine the relationship between mortality and statin adherence using two different approaches to adherence measurement (summary versus repeated-measures). METHODS: A retrospective cohort study was conducted using administrative data from Saskatchewan, Canada between 1994 and 2008. Eligible individuals received a prescription for a statin following hospitalization for acute coronary syndrome (ACS). Adherence was measured using proportion of days covered (PDC) expressed either as: 1) a fixed summary measure, or 2) as a repeatedly measured covariate...
April 20, 2017: BMC Medical Research Methodology
https://www.readbyqxmd.com/read/28427094/statin-therapy-in-patients-undergoing-coronary-artery-bypass-grafting-for-acute-coronary-syndrome
#5
Oliver J Liakopoulos, Elmar W Kuhn, Ingo Slottosch, Matthias Thielmann, Daniel Wendt, Kathrin Kuhr, Heinz Jakob, Thorsten Wahlers
No abstract text is available yet for this article.
April 20, 2017: Thoracic and Cardiovascular Surgeon
https://www.readbyqxmd.com/read/28407684/atorvastatin-inhibits-the-immediate-early-response-gene-egr1-and-improves-the-functional-profile-of-cd4-t-lymphocytes-in-acute-coronary-syndromes
#6
Anna Severino, Chiara Zara, Mara Campioni, Davide Flego, Giulia Angelini, Daniela Pedicino, Ada Francesca Giglio, Francesco Trotta, Simona Giubilato, Vincenzo Pazzano, Claudia Lucci, Antonio Iaconelli, Aureliano Ruggio, Luigi Marzio Biasucci, Filippo Crea, Giovanna Liuzzo
Background- Adaptive immune-response is associated with a worse outcome in acute coronary syndromes. Statins have anti-inflammatory activity beyond lowering lipid levels. We investigated the effects of ex-vivo and in-vivo atorvastatin treatment in acute coronary syndromes on CD4+T-cells, and the underlying molecular mechanisms.Approach and results- Blood samples were collected from 50 statin-naïve acute coronary syndrome patients. We assessed CD4+T-cell activation by flow-cytometry, the expression of 84 T-helper transcription-factors and 84 T-cell related genes by RT-qPCR, and protein expression by Western-blot, before and after 24-hours incubation with increasing doses of atorvastatin: 3-10-26 μg/ml (corresponding to blood levels achieved with doses of 10-40-80 mg, respectively)...
March 14, 2017: Oncotarget
https://www.readbyqxmd.com/read/28397352/effects-of-expanding-the-look-back-period-to-all-available-data-in-the-assessment-of-covariates
#7
Sonja S Nakasian, Jeremy A Rassen, Jessica M Franklin
BACKGROUND: A fixed baseline period has been a common covariate assessment approach in pharmacoepidemiological studies from claims but may lead to high levels of covariate misclassification. Simulation studies have recommended expanding the look-back approach to all available data (AAD) for binary indicators of diagnoses, procedures, and medications, but there have been few real data analyses using this approach. OBJECTIVE: The objective of the study is to explore the impact on treatment effect estimates and covariate prevalence of expanding the look-back period within five validated studies in the Aetion system, a rapid cycle analytics platform...
April 11, 2017: Pharmacoepidemiology and Drug Safety
https://www.readbyqxmd.com/read/28391913/clinical-and-economic-consequences-of-statin-intolerance-in-the-united-states-results-from-an-integrated-health-system
#8
Jove H Graham, Robert J Sanchez, Joseph J Saseen, Usha G Mallya, Mary P Panaccio, Michael A Evans
BACKGROUND: Although statins are considered safe and effective, they have been associated with statin intolerance (SI) in clinical and observational studies. OBJECTIVE: The objective of this study was to describe the clinical and economic consequences of SI through comparison of an SI cohort of patients with matched controls. METHODS: This study used data extracted from an integrated health system's electronic health records from 2008 to 2014...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28391887/investigating-the-prevalence-predictors-and-prognosis-of-suboptimal-statin-use-early-after-a-non-st-elevation-acute-coronary-syndrome
#9
Richard M Turner, Peng Yin, Anita Hanson, Richard FitzGerald, Andrew P Morris, Rod H Stables, Andrea L Jorgensen, Munir Pirmohamed
BACKGROUND: High-potency statin therapy is recommended in the secondary prevention of cardiovascular disease but discontinuation, dose reduction, statin switching, and/or nonadherence occur in practice. OBJECTIVES: To determine the prevalence and predictors of deviation from high-potency statin use early after a non-ST elevation acute coronary syndrome (NSTE-ACS) and its association with subsequent major adverse cardiovascular events (MACE) and all-cause mortality (ACM)...
January 2017: Journal of Clinical Lipidology
https://www.readbyqxmd.com/read/28389125/use-of-cardiovascular-prevention-treatments-after-acute-coronary-syndrome-in-china-and-associated-factors
#10
Emily R Atkins, Xin Du, Yangfeng Wu, Runlin Gao, Anushka Patel, Clara K Chow
BACKGROUND: Prevention of repeat cardiovascular events is an important means of addressing the increasing burden of coronary heart disease in China, however there is minimal information about the use of cardiovascular prevention treatment following acute coronary syndrome (ACS) in China. METHODS: We analysed data from baseline and 6, 12, 18, and 24-month follow-up surveys of 15,140 consecutive ACS patients recruited in 70 hospitals from 17 provinces of China. We describe the use of indicated cardiovascular prevention medicines, risk factor control, change over time and factors associated with continued prevention...
March 27, 2017: International Journal of Cardiology
https://www.readbyqxmd.com/read/28379032/success-and-failure-of-cardiovascular-disease-prevention-in-czech-republic-over-the-past-30-years-czech-part-of-the-euroaspire-i-iv-surveys
#11
H Rosolová, B Nussbaumerová, O Mayer, R Cífková, J Bruthans
Cardiovascular (CV) mortality was reduced more than 50 % in the Czech population at the turn of the century, due to an improvement of major CV risk factors in the general population, interventional procedures implemented into the treatment of acute coronary events, and new drugs (ACE inhibitors, statins etc.) for CV prevention (Czech MONICA and post-MONICA studies, 1985-2008). An insufficient level of preventive efforts is described in the Czech patients after acute coronary syndrome (Czech part of the EUROASPIRE studies, 1995-2013)...
April 5, 2017: Physiological Research
https://www.readbyqxmd.com/read/28373930/risk-of-mortality-and-recurrent-cardiovascular-events-in-patients-with-acute-coronary-syndromes-on-high-intensity-statin-treatment
#12
J Rockberg, L Jørgensen, B Taylor, P Sobocki, G Johansson
Several randomized controlled trials have shown a benefit of high-dose intensive statin treatment in reducing risk of death and second cardiovascular disease (CVD) events in patients previously diagnosed with an acute coronary syndrome (ACS). Non-randomized studies in clinical settings support these findings, but large, long-term, observational studies addressing CVD and non-CVD endpoints are lacking. In this retrospective longitudinal study, we followed ACS patients in Sweden during 2001-2012 using national health registry and medical record data...
June 2017: Preventive Medicine Reports
https://www.readbyqxmd.com/read/28372491/community-pharmacy-based-inducement-programs-are-associated-with-better-medication-adherence-a-cohort-study
#13
Scot H Simpson, Mu Lin, Dean T Eurich
BACKGROUND: Inducement programs can promote customer loyalty; however, the clinical effects of these programs are unknown. OBJECTIVE: To examine relationships among inducement program use, medication adherence, and health outcomes. METHODS: Alberta residents with ≥ 1 physician visit for diabetes or hypertension between April 2008 and March 2014 were eligible for this study and included if they were new statin users and alive at least 455 days after the first statin dispensation...
April 1, 2017: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/28347514/use-of-lipid-modifying-therapy-and-ldl-c-goal-attainment-in-a-high-cardiovascular-risk-population-in-the-netherlands
#14
Josephina G Kuiper, Robert J Sanchez, Eline Houben, Edith M Heintjes, Fernie J A Penning-van Beest, Irfan Khan, Melanie van Riemsdijk, Ron M C Herings
PURPOSE: This study investigates lipid-modifying therapy (LMT) and LDL-C goal attainment in a real-world, high-cardiovascular-risk population in the Netherlands. METHODS: From the PHARMO Database Network, patients aged ≥18 years with an LDL-C measurement in 2012 (index date) were selected and hierarchically classified into the following mutually exclusive high-cardiovascular-risk categories: familial hypercholesterolemia (FH), recent acute coronary syndrome (ACS), coronary heart disease, ischemic stroke, peripheral arterial disease, and diabetes mellitus...
March 24, 2017: Clinical Therapeutics
https://www.readbyqxmd.com/read/28335787/risk-factors-of-atherosclerotic-tissue-types-in-single-vessel-and-intermediate-coronary-lesions-a-cross-sectional-study
#15
Xianjin Wang, Qun Chen, Yu Xu, Yanqing Wang, Yang Yang, Ming Gu, Haihua Xu, Yanfang Zhao
BACKGROUND: Few data exist that correlate lesion-related risk factors such as conventional cardiovascular risks or lipoprotein-associated phospholipase A2 (Lp-PLA2) with tissue types within atherosclerotic plaques in patients with single-vessel and intermediate coronary lesions. METHODS: One hundred and ninety-two patients with single-vessel and intermediate coronary lesions were enrolled in a cross-sectional study and divided into two groups: stable angina pectoris (SAP) and acute coronary syndrome (ACS) groups...
March 23, 2017: Lipids in Health and Disease
https://www.readbyqxmd.com/read/28325524/current-status-of-lipid-management-in-acute-coronary-syndrome
#16
REVIEW
Koichiro Fujisue, Kenichi Tsujita
The development of coronary revascularization has dramatically improved early cardiovascular outcomes in patients with acute coronary syndrome (ACS). However, patients who have experienced myocardial infarction (MI) are at high risk of recurrence of cardiovascular events compared with those who are healthy or have stable coronary artery disease. Acute coronary events induce further inflammatory responses and plaque vulnerability in either a coronary culprit or whole vessels. The majority of data have supported the importance of coronary risk management to prevent secondary events...
March 18, 2017: Journal of Cardiology
https://www.readbyqxmd.com/read/28321012/impact-of-lipoprotein-a-on-long-term-outcomes-in-patients-with-coronary-artery-disease-treated-with-statin-after-a-first-percutaneous-coronary-intervention
#17
Satoru Suwa, Manabu Ogita, Katsumi Miyauchi, Taketo Sonoda, Hirokazu Konishi, Shuta Tsuboi, Hideki Wada, Ryo Naito, Tomotaka Dohi, Takatoshi Kasai, Shinya Okazaki, Kikuo Isoda, Hiroyuki Daida
AIMS: Cardiovascular risk persists despite intensive lipid lowering therapy using statins. Serum levels of lipoprotein (a) [Lp(a)] can be a residual cardiovascular risk for adverse events. Aim of the present study was to evaluate the impact of Lp(a) on long-term clinical outcomes in patients treated with statin after percutaneous coronary intervention. METHODS: We prospectively enrolled 3507 consecutive CAD patients who underwent a first percutaneous coronary intervention (PCI) between 1997 and 2011 at our institution...
March 17, 2017: Journal of Atherosclerosis and Thrombosis
https://www.readbyqxmd.com/read/28294854/-registry-of-acute-coronary-syndromes-record-3-characteristics-of-patients-and-treatment-during-initial-hospitalization
#18
A D Erlikh, N A Gratsiansky On Behalf Of Record-Participants
Acute Coronary Syndrome (ACS) Registries RECORD 1-2 (2007-2001) gave valuable information on management of ACS patients in Russia. RECORD-3 was carried out in March-April, 2015. Here we present characteristics of included patients (pts) and data on their treatment during initial hospitalization. MATERIAL AND METHODS: RECORD-3 recruited pts with suspected ACS consecutively hospitalized in participating hospitals (n=47, 55% "invasive") during 1 month. RESULTS: Number of included pts was 2370 (39% women, mean age 64...
April 2016: Kardiologiia
https://www.readbyqxmd.com/read/28291866/long-term-safety-and-efficacy-of-achieving-very-low-levels-of-low-density-lipoprotein-cholesterol-a-prespecified-analysis-of-the-improve-it-trial
#19
Robert P Giugliano, Stephen D Wiviott, Michael A Blazing, Gaetano M De Ferrari, Jeong-Gun Park, Sabina A Murphy, Jennifer A White, Andrew M Tershakovec, Christopher P Cannon, Eugene Braunwald
Importance: In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial, intensive low-density lipoprotein cholesterol (LDL-C)-reducing therapy with ezetimibe/simvastatin compared with simvastatin alone was associated with a significant reduction in cardiovascular events in 18 144 patients after acute coronary syndrome. The safety of very low LDL-C levels over the long-term is unknown. Objective: To assess the safety and clinical efficacy of achieving a very low (<30 mg/dL) level of LDL-C at 1 month using data from the Improved Reduction of Outcomes: Vytorin Efficacy International Trial...
March 14, 2017: JAMA Cardiology
https://www.readbyqxmd.com/read/28291622/a-randomized-controlled-comparison-of-different-intensive-lipid-lowering-therapies-in-chinese-patients-with-non-st-elevation-acute-coronary-syndrome-nste-acs-ezetimibe-and-rosuvastatin-versus-high-dose-rosuvastatin
#20
Dan Ran, Hui-Juan Nie, Yu-Lin Gao, Song-Bai Deng, Jian-Lin Du, Ya-Jie Liu, Xiao-Dong Jing, Qiang She
BACKGROUND: Statin combined with ezetimibe demonstrates significant benefit in lowering low density lipid cholesterol (LDL-C) and cardiovascular events abroad, but whether intermediate intensity statins combined with ezetimibe is superior to high-intensity statin monotherapy in Chinese people is unknown. METHODS: A total of 125 patients were randomly assigned to a intermediate intensity rosuvastatin group (rosuvastatin 10mg/d, n=42), high-dose rosuvastatin group (rosuvastatin 20mg/d, n=41) or combination therapy group (ezetimibe 10mg/d and rosuvastatin 10mg/d, n=42) with a 12-week follow-up...
May 15, 2017: International Journal of Cardiology
keyword
keyword
45397
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"